LUCENT-1 and -2: Extended induction response with mirikizumab over time in UC
In this medfyle
Not all patients respond to induction by Week 12, but extended induction could give incremental improvements over time in early non-responders. New data from LUCENT look at extended induction across a range of clinical and symptomatic outcomes.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Source: Rubin DT, Charabaty A, Jairath V, et al. P901 Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and -2 trials. J Crohns Colitis 2024;18(suppl1):jjad212.1031 [P901]
The information and data provided is for information purposes only.
The author(s) of the original article had no involvement in the creation of this content.
